Albarel (rilmenidin) --a selective I1 imidazole receptor agonist. Pharmacologic properties and experience in clinical use
Khirmanov, V.N.
Terapevticheskii Arkhiv 75(2): 85-88
2003
ISSN/ISBN: 0040-3660 PMID: 12685403 Document Number: 559868
Document emailed within 1 workday
Related Documents
Rutkowska, M.; Jachimczuk, O. 2004: Antidepressant--like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors Acta Poloniae Pharmaceutica 61(2): 165-167Hahn, R.A.; MacDonald, B.R.; Martin, M.A. 1983: Antihypertensive activity of LY141865, a selective presynaptic dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 224(1): 206-214
Zhu, D.; Wang, L.; Li, Y.; Zhu, Y.; Zhao, P. 2010: Effects of retinoic acid receptor agonist and retinoid X receptor agonist on the expression of IL-4 and IFN-gamma in cord blood mononuclear cells Wei Sheng Yan Jiu 39(4): 433-435
Kwatra, M.M.; Ptasienski, J.; Hosey, M.M. 1989: The porcine heart M2 muscarinic receptor: agonist-induced phosphorylation and comparison of properties with the chick heart receptor Molecular Pharmacology 35(5): 553-558
Wahhab, A.; Smith, J.R.; Ganter, R.C.; Moore, D.M.; Hondrelis, J.; Matsoukas, J.; Moore, G.J. 1993: Imidazole based non-peptide angiotensin II receptor antagonists. Investigation of the effect of the orientation of the imidazole ring on biological activity Arzneimittel-Forschung 43(11): 1157-1168
Hahn, R.A.; MacDonald, B.R. 1984: Systemic hemodynamic and regional blood flow effects of LY141865, a selective dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 230(3): 558-568
Sacaan, A.I.; Monn, J.A.; Schoepp, D.D. 1991: Intrastriatal injection of a selective metabotropic excitatory amino acid receptor agonist induces contralateral turning in the rat Journal of Pharmacology and Experimental Therapeutics 259(3): 1366-1370
Hoare, S.R.; Usdin, T.B. 2000: Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity Journal of Pharmacology and Experimental Therapeutics 295(2): 761-770
Haque, M.S.; Sugiyama, K.; Taniguchi, T.; Okada, K.; Nakai, Y.; Kitazawa, Y. 1995: The effects of ETB receptor-selective agonist on IOP and blood-aqueous barrier in rabbit eyes: role of cyclooxygenase products Japanese Journal of Ophthalmology 39(4): 360-367
Koek, W.; Patoiseau, J.F.; Assié, M.B.; Cosi, C.; Kleven, M.S.; Dupont-Passelaigue, E.; Carilla-Durand, E.; Palmier, C.; Valentin, J.P.; John, G.; Pauwels, P.J.; Tarayre, J.P.; Colpaert, F.C. 1998: F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential Journal of Pharmacology and Experimental Therapeutics 287(1): 266-283
Skuza, G.; Kolasiewicz, W. 2001: Repeated treatment with SA4503, a selective sigma1 receptor agonist, up-regulates alpha-adrenergic system. a behavioral study Polish Journal of Pharmacology 53(5): 547-550
Fujitani, Y.; Ueda, H.; Okada, T.; Urade, Y.; Karaki, H. 1993: A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta Journal of Pharmacology and Experimental Therapeutics 267(2): 683-689
Pascuzzo, G.J.; Akaike, A.; Maleque, M.A.; Shaw, K.P.; Aronstam, R.S.; Rickett, D.L.; Albuquerque, E.X. 1984: The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. I. Agonist, desensitizing, and binding properties Molecular Pharmacology 25(1): 92-101
Gopalakrishnan, M.; Monteggia, L.M.; Anderson, D.J.; Molinari, E.J.; Piattoni-Kaplan, M.; Donnelly-Roberts, D.; Arneric, S.P.; Sullivan, J.P. 1996: Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor Journal of Pharmacology and Experimental Therapeutics 276(1): 289-297
Olson, L.J.; Lowe, D.G.; Drewett, J.G. 1996: Novel natriuretic peptide receptor/guanylyl cyclase A-selective agonist inhibits angiotensin II- and forskolin-evoked aldosterone synthesis in a human zona glomerulosa cell line Molecular Pharmacology 50(2): 430-435
Wu, J.; Liang, Y.; Nawaz, Z.; Hyder, S.M. 2005: Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance International Journal of Oncology 27(6): 1647-1659
Malmberg; Mikaels; Mohell, N. 1998: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding Journal of Pharmacology and Experimental Therapeutics 285(1): 119-126
Buck, K.J.; Harris, R.A. 1990: Benzodiazepine agonist and inverse agonist actions on GABAA receptor-operated chloride channels. II. Chronic effects of ethanol Journal of Pharmacology and Experimental Therapeutics 253(2): 713-719
Huidobro-Toro, J.P.; Carpi, A. 1976: Selective blocking properties of chloro acetyl catechol (CAC) on the alpha-adrenergic receptor Archives Internationales de Pharmacodynamie et de Therapie 222(2): 180-192
Muraki, I. 2001: Behavioral and neurochemical study on the mechanism of the anxiolytic effect of a selective serotonin reuptake inhibitor, a selective serotonin1A agonist and lithium carbonate Hokkaido Journal of Medical Science 76(2): 57-70